ImmunityBio director Cheryl Cohen sells 81,056 shares

The reported common-stock sale was made under a Rule 10b5-1 trading plan entered into on February 27, 2026.

Rhea-AI Filing Summary

ImmunityBio, Inc. director Cheryl Cohen exercised options for 55,979 shares at a $2.98 exercise price and acquired 55,979 common shares on October 2, 2026. She also sold 81,056 common shares at $10.50 per share that day. The sale was made pursuant to a Rule 10b5-1 trading plan entered into on February 27, 2026. The option record lists June 14, 2032, as its expiration date.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Cohen Cheryl

Role Director

Sold 81,056 shs ($851K)

Approx. gross sale proceeds $851K

Approx. exercise cost $167K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	55,979	$0.00	$0.00
Exercise	Common Stock	55,979	$2.98	$167K
Sale	Common Stock F1	81,056	$10.50	$851K

Holdings After Transaction: Stock Option (right to buy) — 55,979 contracts (Direct); Common Stock — 100,309 shares (Direct)

Footnotes (1)

1. F1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.

Key Figures

Options exercised: 55,979 shares Option exercise price: $2.98 per share Common shares sold: 81,056 shares +2 more

5 metrics

Options exercised 55,979 shares October 2, 2026

Option exercise price $2.98 per share October 2, 2026

Common shares sold 81,056 shares October 2, 2026

Sale price $10.50 per share October 2, 2026

Option expiration date June 14, 2032 Option record

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), exercise price

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 2.9800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBRX shares did director Cheryl Cohen sell, and at what price?

Cheryl Cohen sold 81,056 common shares at $10.50 per share on October 2, 2026. The sale was made pursuant to a Rule 10b5-1 trading plan entered into on February 27, 2026.

How many IBRX shares did Cheryl Cohen acquire through option exercise?

Cheryl Cohen exercised options for 55,979 shares at a $2.98 exercise price on October 2, 2026, and acquired 55,979 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 06:06 PM Accepted by SEC EDGAR 10/06/2026 - 06:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Cheryl

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2026		M		55,979	A	$2.98	181,365	D
Common Stock	10/02/2026		S(1)		81,056	D	$10.5	100,309	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.98	10/02/2026		M			55,979	06/12/2023	06/14/2032	Common Stock	55,979	$0	55,979	D

Explanation of Responses:

1. The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on February 27, 2026.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)